Zynex Announces Increased Orders in April.

LITTLETON, Colo. -- Zynex Medical Holdings, Inc. (OTCBB: ZYNX), a provider of pain management systems and electrotherapy products for medical patients with functional disability, announces an increase in its orders of 322% for April of 2007 compared to the same month last year and a 6.5% increase over the prior month.

"Our continued increase in orders demonstrates a solid product acceptance, and a continued market penetration as a result of our adding experienced sales persons in the second half of 2006," said Thomas Sandgaard, CEO.

Zynex received 641 orders in April 2007 versus 152 orders twelve months ago and 602 orders in March of 2007. Zynex has not yet finalized its results for the first and second quarters of 2007, including the impact of increased orders. Zynex will state these results in the Forms 10-QSB for the 2007 first and second quarters.

About Zynex Medical Holdings, Inc.

Zynex Medical Holdings, Inc. (founded in 1996) engineers, manufactures, markets and sells its own design of electrotherapy medical devices in two distinct markets: standard digital electrotherapy products for pain relief and pain management; and the NeuroMove(TM) for stroke and spinal cord injury (SCI) rehabilitation. Zynex's product lines are fully developed, FDA-cleared, commercially sold, and have been developed to uphold the Company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain.

Safe Harbor Statement

Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, risks and delays associated with product development, risk of market acceptance of products, technology or product obsolescence, competitive risks, reliance on manufacturing partners, dependence on reimbursement from insurance companies, additional capital needs and other risks described in our Form 10-KSB for the year ended December 31, 2006.